Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.06 and traded as low as $0.06. Nascent Biotech shares last traded at $0.06, with a volume of 41,000 shares.
Nascent Biotech Trading Down 4.0 %
The firm’s 50-day moving average price is $0.06 and its two-hundred day moving average price is $0.06.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Further Reading
- Five stocks we like better than Nascent Biotech
- Manufacturing Stocks Investing
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What is Short Interest? How to Use It
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
